Glyclopyramide

Glyclopyramide
Clinical data
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name 4-chloro-N-[(pyrrolidin-1-ylamino)carbonyl]benzenesulfonamide;
PubChem CID	71793;
UNII	KE474IKG1W;
KEGG	D01799 ;
CompTox Dashboard (EPA)	DTXSID2048822 ;
Chemical and physical data
Formula	C11H14ClN3O3S
Molar mass	303.76 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CCN(C1)NC(=O)NS(=O)(=O)C2=CC=C(C=C2)Cl;
	(verify)

Glyclopyramide (INN, marketed under the tradename Deamelin-S) is a sulfonylurea drug used in the treatment of diabetes. It has been marketed in Japan since 1965.

It is classified as second generation.^[1]

References

^ Ozawa H, Murai Y, Ozawa T (2003). "[A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus]". Yakugaku Zasshi (in Japanese). 38 (1): 11–27. PMID 14570054.{{cite journal}}: CS1 maint: multiple names: authors list (link)

Template:Ja icon Deamelin-S 250 mg Tablets

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

[pmid14570054-1] Ozawa H, Murai Y, Ozawa T (2003). "[A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus]". Yakugaku Zasshi (in Japanese). 38 (1): 11–27. PMID 14570054.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[1]